International law firm Simmons & Simmons has advised private equity firm CBPE Capital (“CBPE”) on its investment in Access Infinity, a leading provider of market access, pricing, and evidence strategy solutions to the global pharmaceutical and biotech industries.
Founded in 2014, Access Infinity has established itself as a trusted partner for life sciences companies globally, providing a suite of software and consulting services that support clients throughout the drug development lifecycle. The firm supports some of the largest pharmaceutical companies in the world.
CBPE is a UK based private equity firm with a strong track record of supporting ambitious, high-growth businesses in the healthcare and technology sectors.
CBPE’s investment in Access Infinity is set to accelerate its growth strategy, further developing its technology platform and expanding its international presence.
The Simmons & Simmons team advising CBPE was led by Richard Kyle, Partner and Head of the firm’s UK Private Equity Group.
Richard Kyle commented: “We are delighted to have supported CBPE on this fantastic deal, leveraging our healthcare, life sciences and technology expertise. Advising CBPE reaffirms our commitment to supporting clients investing in dynamic, growth-focused sectors, and further cements our reputation as a leading adviser to private equity clients on cross-border transactions. We wish the founders of Access Infinity and CBPE every success for their partnership”.
